

1 Supplementary material

2

3 **Legends to supplementary tables**

4

5 **Supplementary table S1**

6 **Coagulation experiments with and without bacteria.** Each row represents a
7 treatment. H-D-Pro-Phe-Arg-CMK is an inhibitor of FXII and PK. P<3 is the fraction
8 of plasma smaller than 3 kDa. S<3 is the fraction of saliva smaller than 3 kDa. S>3 is
9 the fraction of saliva larger than 3 kDa. Fractions are the flow-through and retentate,
10 respectively, from centrifugal filters with a 3 kDa cut-off.

11

12 **Supplementary table S2**

13 List of proteins and protein chains quantified in saliva-plasma clots with and without
14 bacteria using shotgun MS. The intensity values are from three biological replicates
15 per sample-group. The denoted protein groups are the same as used in *fig. 1 c*. The
16 ignored group contains protein chains of which intensity values were omitted in *fig. 1*
17 *c*. The proteins were identified with the Trans Proteomic Pipeline software
18 environment using 1% False Discovery Rate (FDR), and Label-free quantification
19 values were determined by OpenMS. Multiple t-test (one by row) of replicate
20 intensity values calculated with the software GraphPad Prism 6.0 assuming that all
21 rows were sampled from populations with equal variance and the Q-value (FDR) set
22 to 1%.

23

24

25

26 **Supplementary tables**

27

28 **Supplementary table S1**

29 **Coagulation experiments with and without bacteria.**

Coagulation experiments with bacteria				
180 µl saliva	20 µl plasma	4×10 ⁷ cfu G45 bacteria		
180 µl saliva	20 µl plasma	4×10 ⁷ cfu G45 bacteria	10 µg/ml Chloramphenicol	
180 µl saliva	20 µl plasminogen depleted plasma	4×10 ⁷ cfu G45 bacteria	6×10 ⁻⁷ mol CaCl ₂	
180 µl saliva	20 µl plasminogen depleted plasma	4×10 ⁷ cfu G45 bacteria	6×10 ⁻⁷ mol CaCl ₂	4 µg plasminogen
Coagulation experiments without bacteria				
180 µl saliva		20 µl plasma		
180 µl saliva		20 µl plasma	4 µg anti-FVII antibody	
180 µl saliva		20 µl plasma	4 µg control antibody	
180 µl saliva		20 µl plasma	10 µg H-D-Pro-Phe-Arg-CMK	
180 µl saliva		20 µl plasma	1 µg H-D-Pro-Phe-Arg-CMK	
200 µl saliva				
180 µl P<3		20 µl plasma		
180 µl S<3		20 µl plasma		
180 µl S>3 in 8.5 g/l NaCl with 1.7 mM CaCl ₂		20 µl plasma		

180 µl S>3 in 8.5 g/l NaCl with 1.7 mM CaCl ₂	20 µl plasma	4 µg anti-FVII antibody
180 µl S>3 in 8.5 g/l NaCl with 1.7 mM CaCl ₂	20 µl plasma	4 µg control antibody
180 µl S>3 in 8.5 g/l NaCl with 1.7 mM CaCl ₂	20 µl plasma	10 µg H-D-Pro-Phe-Arg-CMK
180 µl S<3	20 µl plasma	4 µg anti-FVII antibody
180 µl S<3	20 µl plasma	10 µg H-D-Pro-Phe-Arg-CMK
47 µl P<3	20 µl plasma	133 µl 1.7 mM CaCl ₂
180 µl S<3	20 µl plasma	1.3 mg NaCl
180 µl 8.5 g/l NaCl with 1.7 mM CaCl ₂	20 µl plasma	
180 µl 2.24 g/l NaCl with 1.7 mM CaCl ₂	20 µl plasma	
180 µl S>3 in 2.24 g/l NaCl with 1.7 mM CaCl ₂	20 µl plasma	

30

31 **Supplementary table S2**

